Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Northwestern University
Modality
Cell therapy
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03072134CT.gov Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anaplastic Oligodendroglioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Neural Stem Cells (this asset) | Northwestern University | P1 | CC · 47 |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| Irinotecan | City of Hope Medical Center | P2 | BB |
| Trametinib | Novartis Pharmaceuticals | P4 | BB |
| Carboplatin | Oliver Jonas | P2 | B |
| Temsirolimus | Andrew B Lassman, MD | P1/2 | B |
| Dabrafenib | Novartis Pharmaceuticals | P4 | B |
| Camustine | Shandong Lanjin Pharmaceuticals Co.,Ltd | P3 | B |
| Perifosine | Andrew B Lassman, MD | P1/2 | B |
+42 more in the Anaplastic Oligodendroglioma cohort
Other indications for Neural Stem Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Anaplastic Oligoastrocytoma | — | P1 | CC · 47 |
| Anaplastic Astrocytoma | — | P1 | CC · 44 |
| Glioblastoma | — | P1 | CC · 44 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Neural Stem Cells in Anaplastic Oligodendroglioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/neural-stem-cells-anaplastic-oligodendroglioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →